Key Highlights
- Total revenue rose 45.6% year over year to RMB432.8 million in Q1 2026, driven by aesthetic-treatment services revenue that jumped 185.8% to RMB282.4 million, while information-and-reservation revenue fell 34.0%.
- So-Young operated 54 branded aesthetic centers across sixteen cities as of March 31, 2026, up from 49 centers in fifteen cities three months earlier, with 41 of 54 centers profitable at the center level.
- Net loss attributable to shareholders widened to RMB49.2 million from RMB33.1 million a year earlier, and gross margin compressed to roughly 42% from about 49%, even as the company extended a $25 million buyback through March 2027.
- So-Young had 54 fully operational branded aesthetic centers as of March 31, 2026 (53 directly operated and one franchised) across sixteen cities including Beijing, Shanghai, Guangzhou, Shenzhen and, newly added, Nanjing, up from 49 centers in fifteen cities three months earlier.
So-Young International Inc. (NASDAQ:SY) is trading its old identity as a medical-aesthetics information platform for a harder, capital-intensive one: operating its own network of aesthetic-treatment clinics across China. First-quarter 2026 results show that shift accelerating, with clinic revenue nearly tripling year over year even as overall profitability remains elusive and legacy platform revenue keeps shrinking.
Why So-Young Is Back on Investors' Radar
So-Young International Inc. (SY) built its business as an online reference guide for Chinese consumers shopping for cosmetic procedures, monetizing through subscription and advertising fees paid by listed clinics and doctors. That model weakened for years as fewer providers renewed subscriptions. In response, the company has spent two years becoming an operator of its own branded aesthetic centers: a vertically integrated chain rather than a pure marketplace. The shift shows in the numbers: in its May 22, 2026 unaudited first-quarter release, So-Young reported aesthetic-treatment services revenue of RMB282.4 million, up 185.8% from RMB98.8 million a year earlier, while total revenue grew 45.6% to RMB432.8 million. That combination of accelerating growth and a business-model pivot is drawing renewed attention to a stock long associated with shrinking revenue and losses.
Business Model: From Listings Platform to Clinic Operator
So-Young generates revenue from four lines, all disclosed in its Q1 2026 release: aesthetic-treatment services through its own branded centers; information-and-reservation services, the legacy business connecting users with third-party providers; sales of medical products and maintenance services, including equipment and injectable products from its Wuhan Miracle subsidiary; and other services such as insurance brokerage. Information-and-reservation revenue fell 34.0% to RMB80.3 million as fewer providers paid for subscriptions, medical-products-and-maintenance revenue rose 2.8% to RMB57.1 million, and other services fell 39.3% to RMB12.9 million. So-Young is a Cayman Islands holding company that consolidates its mainland China business through VIE arrangements rather than direct equity ownership, a structure its 20-F flags as a source of legal uncertainty.
Catalyst: So-Young's (SY) Clinic Buildout Is Reshaping the Revenue Mix
The clearest catalyst is the pace of the aesthetic-center rollout. So-Young had 54 fully operational branded aesthetic centers as of March 31, 2026 (53 directly operated and one franchised) across sixteen cities including Beijing, Shanghai, Guangzhou, Shenzhen and, newly added, Nanjing, up from 49 centers in fifteen cities three months earlier. Verified treatment visits reached approximately 148,000, more than double the 54,400 a year earlier, and verified treatments surpassed 325,800, versus about 123,400. Core members, who contributed over 80% of aesthetic-treatment revenue with a quarterly repurchase rate near 80%, grew by over 11,700, a roughly 22% sequential increase. Management reported 41 of 54 centers were profitable at the center level and 48 generated positive operating cash flow.
First-Quarter 2026 Performance in Detail
Gross profit was RMB181.8 million versus RMB145.9 million a year earlier, but gross margin declined to roughly 42.0% of revenue from about 49.1%, as costs shifted toward the labor- and consumables-intensive clinic business; cost of aesthetic-treatment services rose 156.4% to RMB205.8 million. Total operating expenses rose 26.6% to RMB239.7 million: sales-and-marketing spending climbed 33.7% to RMB130.8 million and general-and-administrative expenses rose 42.5% to RMB84.5 million, both tied to center expansion, while research-and-development spending fell 24.2% to RMB24.3 million. Loss from operations widened to RMB57.9 million (US$8.4 million) from RMB43.4 million. Net loss attributable to shareholders was RMB49.2 million (US$7.1 million), versus RMB33.1 million, and loss per ADS was RMB0.48, versus RMB0.32. Every 13 ADSs represent 10 Class A ordinary shares.
Cash Position, Buyback and Funding Profile
As of March 31, 2026, cash, restricted cash, term deposits and short-term investments totaled RMB880.0 million (US$127.6 million), down from RMB936.4 million at December 31, 2025, on continued investment in center buildouts. Short-term borrowings rose to RMB119.7 million from RMB39.8 million. So-Young carries little long-term debt and funds expansion mostly from its own cash. The board's share-repurchase program (authorized in March 2024 for up to $25 million of ADSs or ordinary shares) was extended in March 2026 through March 31, 2027, with approximately 4.8 million ADSs repurchased across 2024 and 2025.
Growth Runway and What Comes Next
Management expects second-quarter 2026 aesthetic-treatment-services revenue of RMB307.0 million to RMB317.0 million, implying growth of 112.6% to 119.5% year over year. Center-maturity data is instructive: centers open more than twelve months averaged RMB7.5 million in quarterly revenue, versus RMB4.76 million for four-to-twelve-month centers and RMB2.09 million for centers under three months: a curve that should support margins as newer cohorts mature. The question is whether center-level profitability, already at 41 of 54 locations, can translate into consolidated operating profit.
Material Risks Facing So-Young International
So-Young's China-based operations carry risks beyond ordinary competition. Regulatory risk is significant: its 20-F for fiscal 2025, filed April 23, 2026, states it lacks an Audio-Visual License some regulators could argue its short-video content requires, and that mainland China authorities hold broad discretion over online medical-aesthetic providers, offshore-listing filings, cybersecurity reviews and clinic licensing. Consumer-demand risk shows in the multi-year decline of information-and-reservation revenue, down 34.0% in Q1 2026 and 32.2% for full-year 2025, reflecting softer discretionary spending and fewer paid provider subscriptions. Corporate-structure risk stems from reliance on VIE arrangements rather than direct ownership; the 20-F warns these "may not be as effective as direct ownership" and have not been tested in mainland China courts, with consolidated affiliated entities generating 75.2% of 2025 revenue.
Under the Holding Foreign Companies Accountable Act, So-Young was named a Commission-Identified Issuer in 2022 after the PCAOB could not inspect its China-based auditor; that determination was later vacated, and the company does not expect redesignation after its latest 20-F. It also booked RMB19.7 million of long-lived-asset impairment in the fourth quarter of 2025.
Outlook
The bull case rests on the center network reaching a scale where mature-store economics (already visible in the RMB7.5 million average quarterly revenue per center older than twelve months) outweigh ramp-up costs and the shrinking legacy business, returning So-Young to operating profitability. The base case is a continuation of the current pattern: clinic-driven revenue growth alongside narrowing but persistent net losses, funded by an RMB880 million cash position. The downside case involves softer consumer demand for elective procedures in China, continued erosion of the information-services business, clinic build-out cost pressure, and any adverse shift in mainland China's regulatory posture toward online medical advertising or overseas-listed issuers. No prediction is made about where the ADS price will trade; investors should weigh progress against the risks disclosed in the company's filings.
Conclusion
So-Young International Inc. (SY) enters the second half of 2026 in transition: from an advertising-dependent listings platform toward a clinic operator with real, if uneven, unit economics. First-quarter 2026 results confirm the aesthetic-treatment segment is scaling quickly and many centers are already profitable locally, but consolidated losses persisted and gross margin narrowed. Whether So-Young can convert clinic growth into company-wide profitability, while managing the regulatory and structural risks in its China-based operations, will determine whether this is a genuine turnaround or simply a change in the shape of its losses.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.





_11_19_2026_08_23_11_186799.jpg)
Please wait processing your request...